Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 15/20 | 0.47 |
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455981 | 1.00 | TRPM8 (0.47) | TRPM8PPARAPPARGPPARDSIGMAR1 | |
| SCHEMBL3520901 | 0.83 | POLB (0.47) | TRPM8PPARA | |
| SCHEMBL8653315 | 0.80 | AKT1 (0.50) | PPARAPPARGPPARDPTGS1PTGS2 | |
| SCHEMBL6797538 | 0.80 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL8410197 | 0.79 | TRPM8 (0.49) | TRPM8PPARAPPARGSIGMAR1 | |
| SCHEMBL10506242 | 0.79 | ALDH1A1 (0.45) | PPARA | |
| SCHEMBL19469681 | 0.78 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL22129840 | 0.78 | EPHX2 (0.47) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL22798929 | 0.78 | PPARA (0.44) | PPARAPPARGPPARDPTGS1PTGS2 | |
| SCHEMBL19469595 | 0.78 | PPARA (0.46) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634958-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CHROMAN-CARBOXYLATE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-03-15 | — | — | EP | claimed |
| CN-112770628-B | Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained and compositions comprising same | 斯托斯宾有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109422737-B | Imidazolone androgen receptor antagonist, preparation method and application thereof | 上海时莱生物技术有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-110461321-A | Composition containing N-acetyl diaminobutyric acid | BITOP AG | 2019-11-15 | — | — | CN | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1499306-A4 | BICYCLIC AMIDES | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20050203112-A1 | Bicyclic amides | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
| EP-1499306-A2 | BICYCLIC AMIDES | Merck & Co., Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-0910331-B1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003086288-A2 | BICYCLIC AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0910331-A4 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0910331-A1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997039726-A1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203112-A1 | Bicyclic amides | CNR1, CNR2, FAAH | TRPM8 1178/4885PPARA 387/4885PPARG 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.